The results implied that NR2F1 was independently correlated with unfavorable OS after adjustment for stage, primary therapy outcome, race, age, grade, anatomic neoplasm subdivision, lymphatic and venous invasion, and tumor residual disease (Table 1). Here, NR2F1 is linked to glycogen storage disease VI.